Cancer News and Research

Latest Cancer News and Research

Women with BRCA gene mutations at risk of developing cancers at earlier ages

A new analysis has found that women who develop certain hereditary cancers develop them at earlier ages than women in the previous generation. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results point to the importance of tracking younger ages of cancer diagnosis to determine when to provide counseling, screening, and treatment services.

12 Sep 2011

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

BioSante Pharmaceuticals, Inc., today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

IsoRay, Inc. announced today that the FDA has cleared its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

12 Sep 2011

Women with BRCA gene mutation develop breast cancer earlier than their ancestors

Women with a deleterious gene mutation are diagnosed with breast cancer almost eight years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas MD Anderson Cancer Center.

12 Sep 2011

EpiCept announces FDA's feedback on Ceplene clinical development for AML

EpiCept Corporation today announced that at a recent meeting with the U.S. Food and Drug Administration (FDA) the Company was provided more definitive guidance regarding the clinical development of Ceplene, the Company's lead product administered with interleukin-2 (IL-2) for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission.

12 Sep 2011

Crocus plant to provide a tumor killing “smart bomb”

According to the latest research, a drug derived from plant extracts could wipe out tumors in a single treatment with minimal side effects. Scientists have turned a chemical found in crocuses into a ‘smart bomb’ that targets cancerous tumors. The advantage is that healthy tissue is unharmed, reducing the odds of debilitating side effects. And unlike other side effect-free drugs, it is able to kill off more than one type of the disease, including breast, prostate, lung and bowel cancer. Potentially, all solid tumours could be vulnerable to drugs developed this way, meaning it could be used against all but blood cancers.

12 Sep 2011

ASTMH annual meeting to explore latest research on infectious diseases

The 60th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) -- the largest of its kind in the world -- will bring together in one place global experts who are battling a wide range of bacteria, viruses, parasites and other pathogens that each year kill or sicken hundreds of millions of people.

12 Sep 2011

Lung cancer patients treated in high safety-net burden facilities less likely to undergo surgery

A new study finds that lung cancer patients treated in hospitals that care for a high percentage of uninsured and Medicaid-insured patients, so-called "high safety-net burden facilities," were significantly less likely to undergo surgery that was intended to cure the cancer compared to patients treated at low safety-net burden facilities.

12 Sep 2011

Scientists successfully disrupt function of MYC cancer gene

Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting the gene itself.

12 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers.

12 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome

Roche today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.

12 Sep 2011

Human gliomas release excess levels of glutamate and trigger seizures

Glioma, one of the most deadly and common types of brain tumor, is often associated with seizures, but the origins of these seizures and effective treatments for them have been elusive. Now a team funded by the National Institutes of Health has found that human gliomas implanted in mice release excess levels of the brain chemical glutamate, overstimulating neurons near the tumor and triggering seizures.

12 Sep 2011

Scientists identify 28 blood pressure-associated genetic variants

A new report from scientists at Massachusetts General Hospital (MGH) and their colleagues in centers around the world finds that common variants in 28 regions of DNA are associated with blood pressure in human patients.

12 Sep 2011

NASA selects nine projects to investigate space radiation's effect on human explorers

NASA is funding nine proposals from eight states to investigate space radiation's effect on human explorers. The proposals from researchers in California, Colorado, Florida, Georgia, Maryland, Massachusetts, New York and Texas have a total value of approximately $12 million.

12 Sep 2011

Cancer News and Research

Latest Cancer News and Research

Women with BRCA gene mutations at risk of developing cancers at earlier ages

BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

IsoRay receives FDA clearance for GliaSite radiation therapy system to treat brain cancer

Women with BRCA gene mutation develop breast cancer earlier than their ancestors

EpiCept announces FDA's feedback on Ceplene clinical development for AML

Crocus plant to provide a tumor killing “smart bomb”

ASTMH annual meeting to explore latest research on infectious diseases

Lung cancer patients treated in high safety-net burden facilities less likely to undergo surgery

Scientists successfully disrupt function of MYC cancer gene

LC-MRM could provide better understanding of multiple myeloma drug resistance

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome

Human gliomas release excess levels of glutamate and trigger seizures

Scientists identify 28 blood pressure-associated genetic variants

NASA selects nine projects to investigate space radiation's effect on human explorers

Industry Focus eBook - Immunology (3rd edition) eBook

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Immunology (3rd edition) eBook

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Newsletters you may be interested in